Tumor Trailing for Liver SBRT on the MR-Linac.
Tumor trailing is a treatment delivery technique that continuously adjusts the beam aperture according to the last available time-averaged position of the target. This study investigates whether tumor trailing on a magnetic resonance (MR) linear accelerator (linac) can improve target coverage in liver stereotactic body radiation therapy (SBRT) in the case of baseline motion. For 17 patients with oligometastatic liver disease, midposition SBRT treatment plans (3 × 20 Gy, 11-beam intensity modulated radiotherapy) were created for the Elekta Unity MR-Linac. Treatment was simulated using an in-house-developed delivery emulator. Respiratory motion was modelled as the superposition of periodic motion (patient-specific amplitude, 4-second period) and the following baseline motion scenarios: a continuous linear drift (0.5 mm/min), (2) a single shift halfway through treatment (10 mm), (3) a periodic drift (amplitude: 5 mm, period: 5 minutes), or (4) MR imaging-measured baseline drifts. Delivered dose was calculated under full consideration of the patient and machine motion interplay. In addition, trailing was experimentally validated on the MR-Linac using a programmable motion phantom. The average simulated delivery and beam-on times were 15.9 and 8.7 minutes, respectively. An imaging frequency of ≥1 Hz was deemed necessary for trailing. Trailing increased the median gross tumor volume D98% dose by 1.9 Gy (linear drift), 1.2 Gy (single shift), 0.7 Gy (periodic drift), and 0.5 to 1.5 Gy (measured drifts) per fraction, compared with a conventional delivery. In the phantom experiments, the 3%/2 mm local gamma pass rate nearly doubled to 98% when using trailing. Tumor trailing on the MR-Linac restores target dose in liver SBRT in the case of baseline motion for the presented patient cohort.